Family PracticePulmonologyInternal MedicineEmergency MedicinePharmacyConditionsCopdGeneral HealthSteroidsInfectious DiseaseAntibioticsCOPD
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Feb. 25, 2020 (HealthDay News) -- For adults with exacerbation of chronic obstructive pulmonary disease (COPD), antibiotics and systemic corticosteroids are associated with less treatment failure, according to a review published online Feb. 25 in the Annals of Internal Medicine.
Claudia C. Dobler, M.D., Ph.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues assessed the comparative effectiveness and adverse events (AEs) of pharmacologic interventions for adults with COPD exacerbation. Data were included from 68 randomized controlled trials enrolling adults with exacerbation of COPD that compared pharmacologic therapies to placebo, usual care, or other pharmacologic interventions.
The researchers found that independent of severity of exacerbations in outpatients and inpatients, antibiotics given for three to 14 days were associated with increased resolution of exacerbation and less treatment failure at the end of the intervention (odds ratios, 2.03 and 0.54, respectively) compared with placebo or management without antibiotics. Systemic corticosteroids given for nine to 56 days were associated with less treatment failure at the end of the intervention (odds ratio, 0.01) compared with placebo in outpatients and inpatients, but with a higher number of total and endocrine-related AEs. Insufficient evidence was found for other pharmacologic interventions compared with placebo or usual care in inpatients.
"The results of this systematic review support use of antibiotics and systemic corticosteroids in COPD exacerbations, independent of severity," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022
Read this Next
Other Trending Articles